Eversense® Non-adjunctive Use Study is looking at how well a special device, called the Eversense Continuous Glucose Monitoring (CGM) System, works for people with diabetes. There are two types of diabetes: Type 1 and Type 2. This study will compare using the Eversense device with the usual way of checking blood sugar, called Self-Monitoring of Blood Glucose (SMBG), which uses a blood glucose meter. Participants will first use the SMBG method for 6 months and then switch to the Eversense device for another 6 months. The entire study lasts for 12 months and includes clinic visits and using the Eversense device at home. This device involves two sensors inserted under the skin, each lasting up to 90 days.
- Total study duration is 12 months.
- Participants must be 18 or older with a smartphone.
- Participants will visit clinics and use the device at home.
How understandable was the trial content above?
Hard to understand
Easy to understand